Cardioprotective function of cardiac macrophages

Cardiovascular Research

Volumn 102, Issue 2, 2014, Pages 232-239

  Fujiu, Katsuhito ^a,b,c,d   Wang, Jack ^a   Nagai, Ryozo ^a,c,e  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Funding Program for World Leading Innovative RandD on Science and Technology (FIRST Program)   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Alternative activated; Heart; Heart failure; M2; Macrophage

Indexed keywords

CLODRONIC ACID; CYTOKINE; INTERLEUKIN 12; LIPOSOME; MICRORNA 155; MINERALOCORTICOID RECEPTOR; SCAVENGER RECEPTOR A; SERUM AND GLUCOCORTICOID REGULATED KINASE 1;

BIODIVERSITY; CARDIAC MACROPHAGE; CARDIOVASCULAR EFFECT; FIBROSIS; GENETIC MANIPULATION; HEART FAILURE; HEART FUNCTION; HEART INJURY; HEART MUSCLE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MACROPHAGE; MACROPHAGE ACTIVATION; MATHEMATICAL ANALYSIS; MONOCYTE; NONHUMAN; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; TARGET CELL; TH2 CELL; ANIMAL; CLASSIFICATION; CYTOLOGY; FIBROBLAST; HEART MUSCLE CELL; INFLAMMATION; METABOLISM; PATHOLOGY;

ANIMALS; FIBROBLASTS; HEART FAILURE; HUMANS; INFLAMMATION; MACROPHAGES; MONOCYTES; MYOCYTES, CARDIAC;

EID: 84899065916     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu059     Document Type: Review

References (67)

1. Fujiu K Nagai R. Contributions of cardiomyocyte-cardiac fibroblast-immune cell interactions in heart failure development. Basic Res Cardiol 2013;108:357
2. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35
3. Hume DA. Plenary perspective: The complexity of constitutive and inducible gene expression in mononuclear phagocytes. J Leukoc Biol 2012;92:433-444
4. Schulz C Gomez Perdiguero E Chorro L Szabo-Rogers H Cagnard N Kierdorf K Prinz M Wu B Jacobsen SE Pollard JW Frampton J Liu KJ Geissmann F. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012;336: 86-90.
5. Hoeffel G Wang Y Greter M See P Teo P Malleret B Leboeuf M Low D Oller G Almeida F Choy SH Grisotto M Renia L Conway SJ Stanley ER Chan JK Ng LG Samokhvalov IM Merad M Ginhoux F. Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. J Exp Med 2012;209:1167-1181
6. Ginhoux F Greter M Leboeuf M Nandi S See P Gokhan S Mehler MF Conway SJ Ng LG Stanley ER Samokhvalov IM Merad M. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010;330:841-845
7. Locati M Mantovani A Sica A. Chapter six-macrophage activation and polarization as an adaptive component of innate immunity. In: Kenneth MM Miriam M eds. Advances in Immunology. San Francisco: Academic Press; 2013. p. 163-184
8. Davies LC Jenkins SJ Allen JE Taylor PR. Tissue-resident macrophages. Nat Immunol 2013;14:986-995
9. Swirski FK Nahrendorf M Etzrodt M Wildgruber M Cortez-Retamozo V Panizzi P Figueiredo JL Kohler RH Chudnovskiy A Waterman P Aikawa E Mempel TR Libby P Weissleder R Pittet MJ. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009;325:612-616
10. Geissmann F Manz MG Jung S Sieweke MH Merad M Ley K. Development of monocytes macrophages and dendritic cells. Science 2010;327:656-661
11. Robbins CS Hilgendorf I Weber GF Theurl I Iwamoto Y Figueiredo JL Gorbatov R Sukhova GK Gerhardt LM Smyth D Zavitz CC Shikatani EA Parsons M van Rooijen N Lin HY Husain M Libby P Nahrendorf M Weissleder R Swirski FK. Local proliferation Dominates lesional macrophage accumulation in atherosclerosis. Nat Med 2013;19:1166-1172
12. Murray PJ Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723-737
13. Frith JC Monkkonen J Blackburn GM Russell RG Rogers MJ. Clodronate and liposomeencapsulated clodronate are metabolized to a toxic ATP analog adenosine 5'-(beta gamma-dichloromethylene) triphosphate by mammalian cells in vitro. J Bone Miner Res 1997;12:1358-1367
14. Nahrendorf M Swirski FK Aikawa E Stangenberg L Wurdinger T Figueiredo JL Libby P Weissleder R Pittet MJ. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007;204:3037-3047
15. Zandbergen HR Sharma UC Gupta S Verjans JW van Den Borne S Pokharel S van Brakel T Duijvestijn A van Rooijen N Maessen JG Reutelingsperger C Pinto YM Narula J Hofstra L. Macrophage depletion in hypertensive rats accelerates development of cardiomyopathy. J Cardiovasc Pharmacol Ther 2009;14:68-75
16. van Amerongen MJ Harmsen MC van Rooijen N Petersen AH van Luyn MJ. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol 2007;170:818-829
17. RenW Zhang R Markel DC Wu B Peng X Hawkins MWooley PH. Blockade of vascular endothelial growth factor activity suppresses wear debris-induced inflammatory osteolysis. J Rheumatol 2007;34:27-35
18. Nacu N Luzina IG Highsmith K LockatellV Pochetuhen K Cooper ZA GillmeisterMP ToddNW Atamas SP. Macrophages produce TGF-beta-induced (beta-Ig-H3) following ingestion of apoptotic cells and regulate MMP14 levels and collagen turnover in fibroblasts. J Immunol 2008;180:5036-5044
19. Yan DWang X Li D LiuW Li M Qu Z Ruan Q. Macrophages overexpressing VEGF target to infarcted myocardium and improve neovascularization and cardiac function. Int J Cardiol 2013;164:334-338
20. Johnson CR KitzD Little JR.Amethod for the derivation and continuous propagation of cloned murine bone marrow macrophages. J Immunol Methods 1983;65:319-332
21. Varin A Mukhopadhyay S Herbein G Gordon S. Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretion. Blood 2010;115:353-362
22. Stein M Keshav S Harris N Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation. J Exp Med 1992;176:287-292
23. Ishii MWenH Corsa CAS Liu T Coelho AL Allen RM CarsonWF Cavassani KA Li X LukacsNW Hogaboam CM Dou Y Kunkel SL. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 2009;114:3244-3254
24. Cihakova D Barin JG Afanasyeva M Kimura M Fairweather D Berg M Talor MV Baldeviano GC Frisancho S Gabrielson K Bedja D Rose NR. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol 2008;172:1195-1208
25. Yang M Zheng J Miao YWang Y CuiW Guo J Qiu S Han Y Jia L Li H Cheng J Du J. Serum-glucocorticoid regulated kinase 1 regulates alternatively activated macrophage polarization contributing to angiotensin II-induced inflammation and cardiac fibrosis. Arterioscler Thromb Vasc Biol 2012;32:1675-1686
26. Li Y Zhang C Wu Y Han Y CuiW Jia L Cai L Cheng J Li H Du J. Interleukin-12p35 deletion promotes CD4 T-cell-dependent macrophage differentiation and enhances angiotensin II-induced cardiac fibrosis. Arterioscler Thromb Vasc Biol 2012;32:1662-1674
27. Hu Y Zhang H Lu Y Bai H Xu Y Zhu X Zhou R Ben J Chen Q. Class a scavenger receptor attenuates myocardial infarction-induced cardiomyocyte necrosis through suppressing M1 macrophage subset polarization. Basic Res Cardiol 2011;106:1311-1328
28. Brilla CG Matsubara LSWeber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993;71:12A-16A.
29. Pitt B Zannad FRemmeWJCodyR Castaigne A Perez A Palensky J Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999;341:709-717
30. Zannad F Alla F Dousset B Perez A Pitt B InvestigatorsobotR. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 2000;102:2700-2706
31. Kuster GM Kotlyar E Rude MK Siwik DA Liao R Colucci WS Sam F. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation 2005; 111:420-427
32. Pitt B Remme W Zannad F Neaton J Martinez F Roniker B Bittman R Hurley S Kleiman J Gatlin M. Eplerenone a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321
33. Zannad F McMurray JJ Krum H van Veldhuisen DJ Swedberg K Shi H Vincent J Pocock SJ Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21
34. Usher MG Duan SZ Ivaschenko CY Frieler RA Berger S Schutz G Lumeng CN Mortensen RM. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 2010;120: 3350-3364
35. Sheppard KE Autelitano DJ. 11beta-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart. Endocrinology 2002;143:198-204
36. Nahrendorf M Swirski FK. Monocyte and macrophage heterogeneity in the heart. Circ Res 2013;112:1624-1633
37. Thorp EB. Contrasting inflammation resolution During atherosclerosis and post myocardial infarction at the level of monocyte/macrophage phagocytic clearance. Front Immunol 2012;3:39
38. Troidl C Mollmann H Nef H Masseli F Voss S Szardien S Willmer M Rolf A Rixe J Troidl K Kostin S Hamm C Elsasser A. Classically and alternatively activated macrophages contribute to tissue remodelling after myocardial infarction. J Cell Mol Med 2009;13:3485-3496
39. Henson PM. Dampening inflammation. Nat Immunol 2005;6:1179-1181
40. Fujiu K Manabe I Nagai R. Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial damage in mice. J Clin Invest 2011;121:3425-3441
41. Lin SL Castano AP Nowlin BT Lupher ML Duffield JS. Bone marrow Ly6chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009;183:6733-6743
42. Epelman S Lavine KJ Beaudin AE Sojka DK Carrero JA Calderon B Brija T Gautier EL Ivanov S Satpathy AT Schilling JD Schwendener R Sergin I Razani B Forsberg EC Yokoyama WM Unanue ER Colonna M Randolph GJ Mann DL. Embryonic and adultderived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 2014;40:91-104
43. Mezzaroma E Toldo S Farkas D Seropian IM Van TassellBW Salloum FN Kannan HR MennaAC VoelkelNF Abbate A. The inflammasomepromotes adverse cardiac remodeling following acute myocardial infarction in the mouse. ProcNatl Acad Sci USA 2011;108: 19725-19730
44. Frangogiannis NG Dewald O Xia Y Ren G Haudek S Leucker T Kraemer D Taffet G Rollins BJ EntmanML. Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation 2007;115: 584-592
45. Nathan C Ding A. Nonresolving inflammation. Cell 2010;140:871-882
46. Wang Y Wang YP Zheng G Lee VW Ouyang L Chang DH Mahajan D Coombs J Wang YM Alexander SI Harris DC. Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 2007;72:290-299
47. Harel-Adar T Mordechai TB Amsalem Y Feinberg MS Leor J Cohen S. Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proc Natl Acad Sci 2011;108:1827-1832
48. Wang Y Yang T Ma Y Halade GV Zhang J Lindsey ML Jin YF. Mathematical modeling and stability analysis of macrophage activation in left ventricular remodeling postmyocardial infarction. BMC Genomics 2012;13(Suppl 6):S21
49. Jin YF Han HC Berger J Dai Q Lindsey ML. Combining experimental and mathematical modeling to reveal mechanisms of macrophage-dependent left ventricular remodeling. BMC Syst Biol 2011;5:60
50. Heymans S Corsten MF VerhesenW Carai P van Leeuwen RE Custers K Peters T Hazebroek M Stoger L Wijnands E Janssen BJ Creemers EE Pinto YM Grimm D Schurmann N Vigorito E Thum T Stassen F Yin X Mayr M de Windt LJ Lutgens E Wouters K de Winther MP Zacchigna S Giacca M van Bilsen M Papageorgiou AP Schroen B. Macrophage MicroRNA-155 promotes cardiac hypertrophy and failure. Circulation 2013;128:1420-1432
51. Corsten MF Papageorgiou A Verhesen W Carai P Lindow M Obad S Summer G Coort SL Hazebroek M van Leeuwen R Gijbels MJ Wijnands E Biessen EA De Winther MP Stassen FR Carmeliet P Kauppinen S Schroen B Heymans S. MicroRNA profiling identifies MicroRNA-155 as an adverse mediator of cardiac injury and dysfunction During acute viral myocarditis. Circ Res 2012;111:415-425
52. OConnell RM Kahn D Gibson WS Round JL Scholz RL Chaudhuri AA Kahn ME Rao DS Baltimore D. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 2010;33:607-619
53. Dudda Jan C Salaun B Ji Y Palmer Douglas C Monnot Gwennaelle C Merck E Boudousquie C Utzschneider Daniel T Escobar Thelma M Perret R Muljo Stefan A Hebeisen M Rufer N Zehn D Donda A Restifo Nicholas P Held W Gattinoni L Romero P. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 2013;38:742-753
54. Hu R Huffaker TB Kagele DA Runtsch MC Bake E Chaudhuri AA Round JL OConnell RM. MicroRNA-155 confers encephalogenic potential to Th17 cells by promoting effector gene expression. J Immunol 2013;190:5972-5980
55. Takeda N Manabe I Uchino Y Eguchi K Matsumoto S Nishimura S Shindo T Sano M Otsu K Snider P Conway SJ Nagai R. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 2010;120:254-265
56. Weisensee D Bereiter-Hahn J SchoeppeW Low-Friedrich I. Effects of cytokines on the contractility of cultured cardiac myocytes. Int J Immunopharmacol 1993;15:581-587
57. Sun M Chen M Dawood F Zurawska U Li JY Parker T Kassiri Z Kirshenbaum LA Arnold M Khokha R Liu PP. Tumor necrosis factor-A mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 2007;115: 1398-1407
58. Katz SD Rao R Berman JW Schwarz M Demopoulos L Bijou R LeJemtel TH. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 1994;90:12-16
59. Flynn JL Goldstein MM Chan J Triebold KJ Pfeffer K Lowenstein CJ Schreiber R Mak TW Bloom BR. Tumor necrosis factor-Alpha is required in the protective immune response against mycobacterium tuberculosis in mice. Immunity 1995;2: 561-572
60. Wesemann DR Benveniste EN. STAT-1aand IFN-g as modulators of TNF-Asignaling in macrophages: Regulation and functional implications of the TNF receptor 1: STAT-1a complex. J Immunol 2003;171:5313-5319
61. Maini RN Elliott MJ Brennan FM Feldmann M. Beneficial effects of tumour necrosis factor-Alpha (TNF-Alpha) blockade in rheumatoid arthritis (RA). Clin Exp Immunol 1995;101:207-212
62. Mann DLMcMurray JJV Packer M Swedberg K Borer JS Colucci WSDjian J Drexler H Feldman A Kober L Krum H Liu P Nieminen M Tavazzi L van Veldhuisen DJ Waldenstrom AWarren MWestheim A Zannad F Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (renewal). Circulation 2004;109:1594-1602
63. Chung ES Packer M Lo KH Fasanmade AA Willerson JT Investigators ftA. Randomized double-blind placebo-controlled pilot trial of infliximab a chimeric monoclonal antibody to tumor necrosis factor-A in patients with moderate-To-severe heart failure: Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003;107:3133-3140
64. Liu Y Yu XY Lin QX Yang M Shan ZX Zheng M. Relationship between macrophage migration inhibitory factor and cardiac function in patients with congestive heart failure. Di Yi Jun Yi Da Xue Xue Bao 2003;23:1169-1170
65. Ohta HWada H Niwa T Kirii H Iwamoto N Fujii H Saito K Sekikawa K Seishima M. Disruption of tumor necrosis factor-Alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005;180:11-17
66. Schreyer SA Peschon JJ LeBoeuf RC. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J Biol Chem 1996;271:26174-26178
67. Witsell AL Schook LB. Tumor necrosis factor alpha is an autocrine growth regulator during macrophage differentiation. Proc Natl Acad Sci 1992;89:4754-4758